Brewers Search for Growth, Eye Cannabis Infusions

Brewers Search for Growth, Eye Cannabis Infusions

$BUD, $TAP, $STZ, $TLRY

The brewers of Budweiser, Coors and other large-scale brewers are placing their bets on cannabis as a way to fight saturated markets and shifting consumer trends.

For years, the industry’s largest players struggled with stagnating markets and shifting consumer tastes.

Anheuser-Busch InBev, Molson Coors and Corona brewer Constellation Brands (NYSE:STZ) have responded by buying up fast-growing craft brews.

Anheuser-Busch’s Y 2011 purchase of Chicago’s Goose Island is 1 of the most emblematic examples of this strategy, which has helped big brewers maintain revenue and profit steady. But concerns over growth continue to hang over the beer industry.

The craft beer segment of the industry has slowed considerably since Y 2016, according to trade association the Beer Institute.

“This seems to be running out of steam now,” said the head of alcoholic drinks at market research provider Euromonitor International.

While the same macroeconomic issues of saturated markets and consumers constantly looking for something new remain, the industry may have to contend with escalating trade issues and a market downturn that could cut into consumer spending.

The larger players are fighting back by pushing into the cannabis industry as a potential engine for future growth.

Anheuser-Busch said last month that it would partner with medicinal cannabis maker Tilray Inc.(NYSE:TLRY) to develop nonalcoholic drinks containing cannabis.

Constellation raised its stake in Canadian cannabis maker Canopy Growth to 38% from 9% in Y 2018. Molson Coors holds a 59% stake in cannabis producer Hydropothecary.

This is the area that we expect the most interesting development to happen, as Cannabis could be the big disruptor.

Constellation, in its latest conference call with analysts and investors, said the “emerging cannabis space represents 1 of the most significant global growth opportunities of the next decade and frankly our lifetime.”

The new strategy is not without risks, however. Constellation shares took a dive recently, seemingly over concerns centering around its cannabis investment.

Wall Street is cautious about the potential return on those investments, considering the legal hurdles that still need to be cleared in Key markets, including the US

Investors should soon get some insight into how several of these brewers’ cannabis plans are faring, as Molson Coors reports Q-4 results on 12 February and Anheuser-Busch reports results on 28 February.

Have a terrific Holiday weekend.

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

You must be logged in to post comments :  
CONNECT WITH